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ABSTRACT
Background/Aims: Recent molecular data suggest
that genetic factors may underlie the disease hetero-
geneity observed in Crohn's disease (CD). It was also
suggested that familial inflammatory bowel disease
(IBD) is a homogenous subgroup, phenotypically dif-
ferent from sporadic disease. Our aim was to deter-
mine the clinical presentation in a large CD popula-
tion.
Methodology: 564 CD patients (m/f: 278/286, age:
37.4 (SD 12.7) yrs, duration: 8.4 (7.1) yrs) were
included. Disease phenotype was determined accord-
ing to Vienna classification. Familial disease, extrain-
testinal manifestations (EIM), need for surgery and
smoking habits were also analyzed. 
Results: Familial IBD was present in 73 (12.9%)
patients. Age at onset and presence of EIMs was asso-
ciated with familial disease. Penetrating (44.6% 
vs. <10yrs: 29.1%, P<0.0001) and ileocolonic disease
(54.4% vs. 42.8%, P=0.03) were more common in
patients with a disease duration of ≥10yrs. In a logis-
tic regression model female gender, colonic/ileocolonic
location, smoking and familial IBD were independent
risk factors for EIMs, while ileal and non-inflamma-
tory disease increased the risk for resections. Smok-
ing was also associated with frequent relapses.
Conclusions: Familial IBD was associated with the
presence of EIMs, while ileal involvement and non-
inflammatory behavior independently increased the
risk for surgery. Since penetrating and extensive dis-
ease was more frequent in patients with longer dis-
ease duration our data support a possible change in
location and behavior during the course of disease. 
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INTRODUCTION
Inflammatory bowel diseases (IBD) are multifacto-
rial, polygenic diseases with probable genetic hetero-
geneity. In this hypothesis, different genetic back-
grounds may explain different clinical patterns of the
disease (1-3). In addition to genetic predisposition, var-
ious environmental and host factors (e.g. genetic-,
epithelial-, immune and non-immune) play a major
role in the pathogenesis of IBD. Crohn's disease (CD)
is a chronic inflammatory disorder of the gastrointesti-
nal tract. Extensive heterogeneity is observed in terms
of disease presentation, behavior, and response to
treatment (4-6). 
CD has a strong genetic component; recently
NOD2/CARD15 mutations were shown by indepen-
dent groups to be associated with susceptibility to CD
(7,8). However there were significant geographical dif-
ferences regarding the frequency of these alleles, as
they are not found in Japan and China (9,10), and
other disease modifying genes may also exist (8). A life-
time risk of 10-20% to develop IBD was reported in the
presence of an affected first degree relative (4,11,12).
CD patients have an affected first-degree relative with
CD in 2.2-16.2% of cases and with IBD in 5.2-22.5% of
cases (13). The concordance rate of affected siblings
was reported to be as high as 60-80% (14). 
Disease phenotypes that may be genetically deter-
mined have been suggested, including: age at onset,
disease site, behavior, presence of extraintestinal man-
ifestation and need for surgery (11,14-16). Age of onset
was found to be significantly less in familial compared
to sporadic disease (17,18), but this was not replicated
in all studies (19). Polito et al. (18) also showed that
stratification for age at diagnosis of CD is associated to
age-specific phenotypes. Concordance rates of 56-86%
for location and 49-82% for behavior were reported in
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parent-child pairs and sibling pairs (14,17). There is no
consistent difference in location and behavior of CD
between familial and non-familial (sporadic) disease.
Higher frequency of ileal disease, less ileocolonic dis-
ease (19), more colonic disease (20) and also no differ-
ence (21) was reported in familial patients. 
In addition to genetic factors, environmental con-
tributions significantly affect clinical phenotypes and
disease course. The percentage of current smokers in a
group of patients with CD is significantly higher than
that observed in a control population matched for sex
and age (45-55 vs. 30-40%) (6). A meta-analysis by
Calkins (22) and a study by our group (6) estimated an
odds ratio of around 2.0 in current smokers when com-
pared to lifetime non-smokers to develop CD. Tobacco
use had been a risk factor for ileal rather than colonic-
only disease and, particularly heavy tobacco use,
increases disease activity, risk of surgery, postoperative
relapses, and accumulation of fistulae and abscesses
(23,24). However, the harmful effect of smoking on the
course of CD is not a universal finding. No differences
were found in the need for operation or for immuno-
suppressants between smokers and non-smokers in
patients from Israel (25,26), and patients with colonic
involvement only are less sensitive to the harmful
effect of smoking (27).
A positive association between disease location and
behavior was also reported (28), however this was not
replicated in all studies (29). Patients with perianal dis-
ease were more likely to have colonic disease (30)
whereas patients with internal fistulizing disease were
more likely to have ileal or ileocolonic disease and are
more likely to require intestinal resection (31). 
In this study we investigated disease phenotype in
a large Crohn's disease population. We also aimed to
investigate the association between familial disease,
smoking and disease phenotype, and identify factors
affecting disease phenotype, presence of extraintestinal
manifestations and need for resection.
METHODOLOGY
564 unrelated Hungarian patients with CD
(male/female: 278/286, age: 37.4 (SD 12.7) years) were
investigated. CD patients with a convenient diagnosis
and with a follow-up time of at least one year were
included. Average disease duration was: 8.4 (7.1) years.
The diagnosis was based on Lennard-Jones criteria
(32) and each patient has read and signed the informed
consent form. 
The disease phenotype was assessed by filling in a
questionnaire. Age, age at presentation, familial IBD,
location, behavior [according to the Vienna classifica-
tion (28): A1: <40 years at onset, A2: >40 years at
onset, L1: ileal, L2: colonic, L3: ileocolonic, L4: upper
GI, B1: inflammatory, B2: stenosing, B3: penetrating],
perianal involvement, frequent flare up, presence of
extraintestinal manifestations [EIM; arthritis: perifer-
al and axial, ocular manifestations: conjunctivitis,
uveitis, iridocyclitis, skin lesions: erythema nodosum,
pyoderma gangrenosum, and hepatic manifestations:
primary sclerosing cholangitis (PSC)], therapeutic
effectiveness (e.g. steroid and/or immunosuppressive
use and resistance), need for surgery (resections), and
smoking habits were determined (Table 1). Familial
IBD was present in 73 patients (12.9%, 41 1st degree
relatives with CD and 11 with UC; 8 2nd degree rela-
tives with CD and 13 with UC).
The study was approved by the Semmelweis Uni-
versity Regional and Institutional Committee of Sci-
ence and Research Ethics (81/2003).
Statistical methods: Variables were tested for
normality by Shapiro Wilk's W test. T-test with sepa-
rate variance estimates, ANOVA, factorial ANOVA
with post hoc Scheffe test, χ2-test and χ2-test with
Yates correction and logistic regression was used to
test differences in disease phenotype between sub-
groups of CD patients. Odds ratios (OR) were calculat-
ed. Pearson correlation was used to compare age at
onset, age class and year of birth data. A P value of
<0.05 was considered as significant. For the statistical
analysis Statistica 6.1 (Statsoft Inc, OK, USA) was
used.
RESULTS
Age at onset was 28.9 (SD 11.5) years and disease
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TABLE 1 Clinical Characteristics of Crohn's Disease Patients, according to 
the Presence of Familial IBD
Total Familial IBD Sporadic IBD
(n=564) (n=73) (n=491)
Male/female 278/286 33/40 245/246
Age (years) 37.3±12.7 36.3±12.6 37.5±12.8
Age at presentation (years) 28.9±11.5 28.1±11.4 29.1±12.0
Duration (years) 8.4±7.1 8.3±6.6 8.4±7.2
Location L1 140 (24.8%) 18 (24.6%) 122 (24.8%)
L2 155 (27.5%) 24 (32.9%) 131 (26.7%)
L3 264 (46.8%) 31 (42.5%) 233 (47.5%)
L4 5 (0.9%) 0 5 (1.0%)
Behavior B1 232 (41.1%) 28 (38.4%) 204 (41.6%) 
B2 138 (24.5%) 19 (26.0%) 119 (24.2%)
B3 194 (34.4%) 26 (35.6%) 168 (34.2%)
Perianal disease, n (%) 152 (26.9%) 26 (35.6%)* 126 (25.7%)*
Frequent relapse, n (%) 203 (36.0%) 32 (43.9%) 171 (34.9%)
Extraintestinal 202 (35.8%) 36 (49.3%)# 166 (33.8%)#
manifestations, n (%)
Arthritis, n (%) 173 (30.7%) 34 (46.6%)## 139 (28.3%)##
Occular, n (%) 28 (5.0%) 4 (5.5%) 24 (4.9%)
Erythema nodosum/ 51 (9.1%) 4 (5.5%) 47 (9.6%)
Pyoderma, n (%) 
PSC, n (%) 22 (3.9%) 1 (1.4%) 21 (4.3%)
Steroid use/refractory, 475 (84.2%) / 64 (87.7%) / 411 (83.7%) / 
n (%) 64 (13.5%) 13 (20.3%) 51 (12.4%)
Azathioprine /refractory 349 (61.9%) / 51(69.9%) / 298 (60.7%) /
n (%) 24 (6.9%) 5 (9.8%) 19(6.4%)
Operation, n (%) / 237 (42.0%) / 27 (37.0%) / 210 (42.9%) /
multiple resection (%) 64 (11.3%) 6 (8.2%) 58 (11.8%)
Smoking habits no 328 (58.1%) 40 (54.8%) 288 (58.6%)
yes 184 (32.6%) 25 (34.3%) 159 (32.4%)
previous 52 (9.3%) 8 (10.9%) 44 (9.0%)
*P=0.051, #P=0.01, ##P=0.002 between patients with family history of
IBD and without by Yates-corrected χ2.
duration 8.4 (7.1) years, not different in patients with
and without familial IBD (Table 1). Age, age at onset
and duration was mildly lower in males [35.0 (11.7)
yrs vs. 39.7 (13.3) yrs, P=0.00001 age at onset: 27.4
(11.2) yrs vs. 30.5 (11.6) yrs, P=0.001 and duration 7.6
(6.3) yrs vs. 9.1 (7.7) yrs, P=0.01]. There was no asso-
ciation between age at onset and familial IBD (Table
1). A strong negative correlation was found between
age at onset and year of birth (r = -0.83, p<0.0001,
Figure 1). No difference was detected between famil-
ial IBD and sporadic cases.
Disease location was predominantly ileocolonic
(L3: 46.8%), while disease behavior was more bal-
anced. Ileocolonic location was more frequent in
patients with penetrating behavior (54.1% vs. others
42.9%) while inflammatory behavior was more fre-
quent in patients with colonic disease (34.5% vs. oth-
ers 22.8%, P=0.004, Table 2). Age at onset was also
lower in patients with ileocolonic (L3: 26.6 yrs vs. L1:
30.5 yrs and L2: 31.6 yrs, P=0.01 and P=0.0004 by
post hoc Scheffe test) or penetrating (27.1 yrs vs. B1:
29.8 yrs, B3: 30.1 yrs, P<0.048 and P=0.041) disease.
In patients with a disease duration of ≥10 yrs B3
(44.6% vs. <10 yrs: 29.1%) and L3 disease (54.4% vs.
42.8%) was more common while B1 (27.5% vs. 48.3%,
P<0.0001) and L1 (18.6% vs. 28.0%, P=0.03) was less
prevalent (Figure 2). Smoking was associated with
disease behavior but not location; penetrating disease
was more frequent in patients currently smoking
(41.9% vs. 29.5%, P=0.02).
There was a tendency of increased frequency of
perianal disease in patients with familial IBD
(P=0.051). In a logistic regression analysis investigat-
ing the association between gender, location, behavior,
familial IBD and smoking; non-inflammatory behav-
ior (OR=1.89, 95%CI=1.30-2.75, P=0.001) and smok-
ing (OR=1.67, 95%CI=1.16-2.39, P=0.005) were inde-
pendent risk factors for frequent relapses.
Extraintestinal manifestations were more fre-
quent in patients with familial IBD (49.3% vs. spo-
radic: 33.8%, P=0.01) and females (39.9% vs. males:
31.6%, P=0.04). Location (L2-3: 41.3% vs. L1 22.1%)
was also associated to the presence of EIMs in uni-
variate analysis. In a logistic regression analysis inves-
tigating the association between gender, location,
behavior, familial IBD, smoking and the presence of
EIMs gender, behavior, smoking and familial disease
were independently associated with EIMs (Table 3).
Arthritis was also more frequent in patients with
familial IBD (46.6% vs. 28.3%, P=0.002). Ileocolonic
or colonic location (OR=4.29, 95%CI=1.51-12.18,
P=0.006) and smoking (OR=1.88, 95%CI=1.04-3.39,
P=0.02) increased the risk of cutaneous manifesta-
tions.
Steroid and azathioprine use was more frequent in
patients with ileocolonic (steroid use; L3: 89% vs. L1:
74.3%, L2: 85.2%, P=0.0017, azathioprine use; 68.9%
vs. L1: 52.1%, L2: 58.7%, P=0.007) or penetrating dis-
ease (steroid use: 90.7% vs. L1: 76.7%, L2: 87.7%,
P=0.0017, azathioprine use: 73.7% vs. L1: 49.1%, L2:
66.7%, P=0.007). In a logistic regression analysis both
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FIGURE 1 Association between age at onset and year of birth in CD
patients. r = -0.83, P<0.0001 in sporadic CD patients and r = -0.85,
P<0.0001 in patients with familial IBD.
TABLE 2 Association between Disease Location and Behavior in Patients 
with Crohn's Disease
Ileal Colonic Ileocolonic Upper GI Total
Inflammatory 54 (23.3%) 79 (34.0%) 96 (41.4%) 3 (1.3%) 232
Stricturing 46 (33.3%) 27 (19.6%) 63 (45.7%) 2 (1.4%) 138
Penetrating 40 (20.6%) 49 (25.3%) 105 (54.1%) 0 194
Total 140 155 264 5 564
P=0.004.
FIGURE 2 Association between Disease Location, Behavior and 
Duration in CD Patients with More or Less than 10 Years Disease 
Duration
location and behavior were independent predictors of
steroid (Plocation=0.001, Pbehavior<0.0001) and azathio-
prine use (Plocation=0.002, Pbehavior<0.0001).
Logistic regression analysis was used to explore
the effect of familial disease, gender, location, behav-
ior and smoking on the need for surgery. Non-inflam-
matory behavior and ileal involvement were positive-
ly, independently associated to the need for resections
but not gender or familial disease (Table 4). This
association was analyzed also for the need of multiple
resections: the effect of ileal involvement (OR=2.91,
95%CI=1.27-6.65, P=0.01) and non-inflammatory
behavior (OR=15.7, 95%CI=4.8-50.9) remained
unchanged.
DISCUSSION
In this study we investigated the characteristic
traits of familial IBD and association between clinical
data and disease phenotype. In concordance with pre-
vious studies (11,17,18) age at onset was not associat-
ed with familial disease with identical disease duration
and similar smoking habits. Furthermore we con-
firmed the findings of Poilito et al. (18), who showed
age-specific phenotype according to the age at diagno-
sis. In our study more stricturing (A1: 37.8% vs. A2:
17.7%, P=0.0007) and ileocolonic (50.0% vs. 31.3%,
P=0.004) disease was present in A1 patients (<40
years old at diagnosis), while colonic disease (A2:
38.5% vs. A1: 25.2%) and inflammatory behavior
(50.0% vs. 39.3%) was more common in patients with
A2 disease.
We found no association between disease location,
behavior and familial IBD. There is also no consisten-
cy in difference in location and behavior of CD
between familial and non-familial (sporadic) disease in
the literature. In two recent studies using the Vienna
classification, Halme et al. (19) demonstrated a
greater frequency of ileal disease in familial disease
(38 versus 21%) and less ileocolonic (35 vs. 50%). Free-
man et al. (20) also found less ileocolonic disease in
familial disease (32 vs. 43%) but purely colonic disease
(46 vs. 29%) was more frequent in familial cases.
Hampe et al. (21) found no difference between familial
and sporadic disease in terms of disease behavior. Fur-
thermore Carbonnel et al. (33) found more operations
for perforating disease in familial disease.
A possible explanation for this large variation
might be that the patient groups may differ also in
terms of other genetic and/or environmental factors
(like smoking). In our study no difference was found in
smoking habits between familial and sporadic
patients. A further limitation could be if the analysis
was not done at the same timepoint, as disease pheno-
type is dynamic and changes over time (29,34), as
found also in our study. Disease location was more
extensive and behavior shifted towards higher preva-
lence of penetrating disease in patients with longer
disease duration.
Extraintestinal manifestations (EIMs) were found
in one third of the patients. The presence of extrain-
testinal manifestations was higher in familial CD
cases and -beside female gender, colonic and ileo-
colonic disease and smoking- familial disease was an
independent risk factor for EIMs in a logistic regres-
sion analysis. High concordance rates for extraintesti-
nal manifestations were reported previously in subse-
quent CD generation (67-80%) (35). Furthermore in
the study of Hofer et al. (36) beside fistulizing disease
behavior, male gender and corticosteroid treatment
and the presence of extraintestinal manifestations
were found to be associated with earlier reoperations.
In contrast in our study the presence of EIMs was not
associated to need for surgery.
An important question is the clinical outcome
measured by the number of relapses and the need for
CD associated surgery. We found non-inflammatory
behavior and smoking to be independent predictors of
frequent relapses. In the study of Cosnes et al. (37)
current smoking increases the risk of flare-up com-
pared to never-smokers by more than 50%, the same
extent found also in our study. The effect of smoking
in that study was independent of gender, age, duration
of disease and current therapy. Patients with colonic
location were less sensitive. In concordance with pre-
vious data (38,39) smoking was associated with more
frequent penetrating disease. 
The deleterious effect of smoking in CD was par-
ticularly manifest in patients who had been operated
on in previous studies. The cumulative rates of clinical
and surgical recurrence were found to be consistently
more elevated in smokers compared to non-smokers
(40,41). 
The need for steroids and immunosuppressants
was reported to be also increased in smokers com-
pared to non-smokers (23). Moreover, the risk of being
operated on at least once during disease course was
also increased in smokers in most previous studies
(42). In our study ileal disease and most markedly
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TABLE 3 Logistic Regression: Association between Gender, Disease 
Location, Behavior, Familial Disease, Smoking and the Presence 
of Extraintestinal Manifestations
Factor Coefficient P value OR 95%CI
Female gender 0.409 0.026 1.51 1.05-2.16
Ileocolonic or colonic location 0.902 <0.0001 2.47 1.57-3.88
Non-inflammatory behavior 0.308 0.10 1.36 0.94-1.96
Familial disease 0.628 0.016 1.88 1.13-3.12
Smoking 0.440 0.017 1.55 1.08-2.22
The coefficient is equivalent to the natural log of the odds ratio (OR).
TABLE 4 Logistic Regression: Association between Gender, Disease Location,
Behavior, Familial Disease, Smoking and the Need for Resection
Factor Coefficient P value OR 95%CI
Female gender 0.042 0.84 1.04 0.69-1.57
Ileal involvement 1.28 <0.0001 3.59 2.22-5.81
Non-inflammatory behavior 2.64 <0.0001 14.10 8.69-22.77
Extraintestinal manifestation -0.29 0.18 0.75 0.49-1.15
Familial disease -0.34 0.28 0.72 0.39-1.32
Smoking -0.35 0.10 0.71 0.46-1.06
The coefficient is equivalent to the natural log of the odds ratio (OR).
non-inflammatory behavior were associated with
increased risk for surgery and, in concordance with
data in patients from Israel (45,46), no differences
were found in the need for operation or for immuno-
suppressants between smokers and non-smokers. Of
note, in the study of Cosnes et al. immunosuppressive
therapy was suggested to neutralize the effect of
smoking on the need for surgery (43).
In IBD, anticipation was originally suggested by
studies that demonstrated a younger age at onset in
familial compared to sporadic disease, and younger
age at onset and more serious disease in subsequent
family generations (17,29,44). However, in concor-
dance with more recent studies (45,46), our results
suggested that anticipation does not occur in IBD. In
this study, we could not prove an earlier age at onset,
or a difference in disease location, behavior or
increased need for aggressive immunosuppressive
therapy and surgery in patients with familial disease
compared to sporadic patients with identical disease
duration and similar smoking habits. In contrast, age
at onset became lower in the later diagnosed patients,
both in sporadic and familial IBD. 
In summary, the presence of EIMs was associated
with familial IBD. Familial disease, female gender,
colonic involvement and smoking were independently
associated with EIMs, while ileal disease, non-inflam-
matory behavior but not smoking were independent
risk factors increasing the risk for surgery. Since pen-
etrating and more extensive disease was more com-
mon in patients with longer disease duration our data
support a possible change in disease location and
behavior during the course of the disease. 
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